Our Services
Medical Information
Helpful Resources
Published on: 5/22/2026
Nucala blocks interleukin-5 to disrupt eosinophil activation and survival, reducing inflammation and shrinking nasal polyps in chronic rhinosinusitis with nasal polyps. Patients often see reduced congestion, improved sense of smell and fewer courses of oral steroids or need for surgery.
There are several factors to consider, such as eligibility, dosing, timeline, side effects and monitoring; see below to understand more.
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent, often frustrating condition marked by inflamed tissue growths (polyps) in the nasal passages and sinuses. These polyps can lead to congestion, loss of smell, facial pressure, nasal discharge and recurrent infections. Standard treatments include corticosteroid sprays, short courses of oral steroids and, in some cases, surgery. However, for many patients, polyps recur despite these approaches.
Enter Nucala (mepolizumab), a biologic therapy that targets the underlying immune process driving polyp formation and growth. By blocking interleukin-5 (IL-5), a key protein in the activation and survival of eosinophils (white blood cells that fuel inflammation), Nucala reduces tissue swelling and polyp size. Below, we explore how the "nucala injection for chronic rhinosinusitis with nasal polyps" works, who may benefit, what to expect and when to seek medical advice.
By neutralizing IL-5, Nucala interrupts this cycle at the source, leading to fewer eosinophils in nasal tissues and gradual regression of polyps.
This targeted approach is different from broad-spectrum steroids, offering the potential for long-term control with fewer systemic side effects.
Multiple clinical trials have evaluated "nucala injection for chronic rhinosinusitis with nasal polyps," demonstrating:
Patients with higher baseline blood eosinophil counts tend to show the greatest benefit.
Nucala is approved for adults with CRSwNP who:
Your doctor may consider factors such as:
Most patients notice gradual improvement over 3–6 months, with continued gains up to one year.
Common side effects are generally mild to moderate:
Less common but important considerations:
Overall, the targeted nature of Nucala means fewer systemic steroid-related risks like weight gain, bone thinning or elevated blood sugar.
By dampening eosinophil-driven inflammation in the sinuses, patients often experience:
These benefits translate into enhanced daily functioning, work productivity and overall well-being.
Your healthcare team will look at:
If adequate control isn't achieved after 6–12 months, your doctor may:
If you're struggling with persistent nasal congestion, reduced smell, facial pressure or recurrent sinus infections despite standard treatments, you may have uncontrolled CRSwNP fueled by eosinophils. To help clarify your symptoms and prepare for your next doctor's appointment, try this free Medically approved LLM Symptom Checker Chat Bot for personalized guidance based on your specific concerns.
This information is intended to educate about how Nucala works and who might benefit from a "nucala injection for chronic rhinosinusitis with nasal polyps." It is not a substitute for professional medical advice. Always speak to a doctor about any life-threatening or serious symptoms, unexpected side effects or before starting or stopping any medication.
(References)
* Hogg AE, et al. Tissue and peripheral blood eosinophil counts in patients with chronic rhinosinusitis with nasal polyps and severe asthma receiving mepolizumab: a post-hoc analysis. J Allergy Clin Immunol Pract. 2021 Oct;9(10):3746-3755.e1. doi: 10.1016/j.jacip.2021.07.037. Epub 2021 Aug 4. PMID: 34551381.
* Hogg AE, et al. Mepolizumab Treatment of Patients With Chronic Rhinosinusitis With Nasal Polyps Reduces Inflammatory Markers in Nasal Tissue: An Abstract of a Poster Presented at the AAAAI 2021 Virtual Annual Meeting. J Allergy Clin Immunol Pract. 2021 May;9(5):2131-2132. doi: 10.1016/j.jacip.2021.03.013. Epub 2021 Mar 13. PMID: 34005183.
* Dykewicz MS. Biologic-driven Endotypes in Chronic Rhinosinusitis with Nasal Polyps: A Focus on IL-5 Targeting. J Allergy Clin Immunol Pract. 2024 Feb;12(2):332-339. doi: 10.1016/j.jacip.2023.12.016. Epub 2023 Dec 26. PMID: 38318721.
* Fokkens W, Hu H. Clinical efficacy and underlying mechanisms of biologics in chronic rhinosinusitis with nasal polyps. Curr Opin Allergy Clin Immunol. 2024 Feb 1;24(1):28-36. doi: 10.1097/ACI.0000000000000958. Epub 2023 Nov 2. PMID: 37905335.
* Patel DA, Peters AT. Mepolizumab for Chronic Rhinosinusitis With Nasal Polyps. J Allergy Clin Immunol Pract. 2020 Jun;8(6):1790-1798. doi: 10.1016/j.jacip.2020.04.004. Epub 2020 Apr 11. PMID: 32468205.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.